Dr. Wustrow has 25 years of pharmaceutical research and development experience, primarily focused on treatments for disorders affecting the central nervous system. Since joining XenoPort in 2008, he has led efforts on a number of discovery programs and is currently executive director of scientific assessment. Prior to joining XenoPort, he was involved in several successful drug discovery and development efforts at Neurogen and Pfizer. Many of these led to successful IND filings, and programs he has led have achieved clinical proof of concept as treatments for insomnia, anxiety and pain. He is an author or inventor on over 100 publications, presentation abstracts and patents. He received his undergraduate degree from Penn State University and his PhD from the University of Rochester.